Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NACA pseudogene 6 (NACAP6) is a processed pseudogene, formally named as a non-protein-coding copy related to the NACA gene that encodes the alpha subunit of the nascent polypeptide-associated complex. Pseudogenes like NACAP6 do not produce functional proteins and typically arise from gene duplication or retrotransposition events. While some pseudogenes have demonstrated regulatory roles at the RNA level, such as acting as competing endogenous RNAs (ceRNAs) or mRNA decoys that can influence the expression of their parental genes and contribute to cancer-related pathways[1][2][3], there is currently no specific literature evidence that NACAP6 has a verified biological or disease role, nor is it considered a therapeutic target[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NACA pseudogene 6 (NACAP6).